Open Access

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin

  • Authors:
    • Minjie Deng
    • Jiajun Sun
    • Suhong Xie
    • Hui Zhen
    • Yanchun Wang
    • Ailing Zhong
    • Hongqin Zhang
    • Renquan Lu
    • Lin Guo
  • View Affiliations

  • Published online on: July 9, 2019     https://doi.org/10.3892/mmr.2019.10477
  • Pages: 2258-2266
  • Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy is widely used for the treatment of ovarian cancer. Since chemotherapy resistance is the major cause of poor prognosis in patients with ovarian cancer, it is important to identify new methods to improve the efficacy of chemotherapy. Minichromosome maintenance complex component 2 (MCM2), which serves an essential role in DNA replication, has been recently identified as a novel proliferation marker with prognostic implications in multiple types of cancer. However, the role of MCM2 in ovarian cancer and its underlying molecular mechanisms remain unclear. Therefore, in the present study, the biological effects of MCM2 were investigated, particularly with respect to DNA damage and repair. In the present study, short hairpin RNA was employed to knockdown MCM2 expression in the A2780 ovarian cancer cell line. The sensitivity of A2780 cells to carboplatin was assessed by cell colony formation assay. The present results suggested that MCM2 knockdown inhibited the proliferation of tumor cells, induced G0/G1 phase arrest and did not exhibit effects on cell apoptosis. However, MCM2 knockdown significantly decreased the colony formation of A2780 cells treated with carboplatin. Furthermore, knockdown of MCM2 together with carboplatin treatment or UV irradiation increased the protein expression level of γ‑H2A histone family member X and p53 compared with control cells. The present data suggested that the increased sensitivity to carboplatin may occur via the p53‑dependent apoptotic response. Additionally, the present results suggested that knockdown of MCM2 may have therapeutic applications in enhancing the efficacy of carboplatin in patients with ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A. ... Guo, L. (2019). Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin. Molecular Medicine Reports, 20, 2258-2266. https://doi.org/10.3892/mmr.2019.10477
MLA
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A., Zhang, H., Lu, R., Guo, L."Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin". Molecular Medicine Reports 20.3 (2019): 2258-2266.
Chicago
Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A., Zhang, H., Lu, R., Guo, L."Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin". Molecular Medicine Reports 20, no. 3 (2019): 2258-2266. https://doi.org/10.3892/mmr.2019.10477